JPMorgan Reiterates Overweight Rating on Biohaven Pharmaceutical Holding (BHVN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Biohaven (BHVN) stock plunges 20% on drug updates, RBC says buy the weakness
May 29, 2024 10:16 AM EDTBiohaven (NYSE: BHVN) saw its stock plunge more than 20% following the market open on Wednesday, after the company released interim data from a Phase 1 study of its autoimmune drug candidate BHV-1300.
The data showed dose-dependent and rapid reductions in IgG levels within hours of administration. There were no severe adverse events reported, with... More
RBC Capital Defending Biohaven Pharmaceutical Holding (BHVN): 'We Would Be Buyers on Weakness'
May 29, 2024 9:14 AM EDTRBC Capital analyst Leonid Timashev reiterated an Outperform rating and $59.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN).
The analyst comments "This morning BHVN published a press release ahead of their R&D day summarizing the key takeaways, and while we expect additional granularity at the R&D day itself, we note the additional IgG degrader data is supportive of further development in our view. There was clear dose dependence in the data, with 5%, 15%, 30% and 37% pbo-adjusted maximal mean IgG reduction across the first 4 cohorts, which is consistent with the company's modeling.... More
Biohaven Pharma (BHVN) Falls 31% Following Updates from Annual Investor R&D Day
May 29, 2024 8:08 AM EDTBiohaven Pharma (NYSE: BHVN) Falls 31% Following Updates from Annual Investor R&D Day
Reports new positive interim data from the ongoing Phase 1 study of BHV-1300, Biohaven's lead investigational drug from its Molecular Degrader of Extracellular Proteins (MoDE) platformBHV-1300 demonstrates dose-dependent and rapid IgG reductions within hours of administrationNo SAEs, no severe AEs, most AEs were mild, deemed unrelated to study drug and resolved spontaneouslyNo clinically significant changes in LFTs... MoreBiohaven Pharma (BHVN) Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Invest
May 29, 2024 7:31 AM EDTBiohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies, provides an overview of its development and regulatory advances across multiple therapeutic areas, and highlights the progress of its innovative degrader pipeline at the Company's 2024 Investor R&D Day today, held concurrently with the Yale Innovation Summit in New Haven, Connecticut. Members of... More
TD Cowen Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN)
May 28, 2024 9:50 AM EDTTD Cowen analyst Tyler Van Buren reiterated a Buy rating and $55.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN).
The analyst commented, "Ahead of the important BHV-1300 SAD data update at the R&D day tomorrow, we provide a brief preview and... More
